上海莱士：SR604注射液新增血管性血友病患者出血发作预防治疗临床试验申请获受理 全球尚无与该药物同靶点的产品上市

Group 1 - The core point of the article is that Shanghai Laishi has received approval from the National Medical Products Administration for clinical trials of SR604 injection for the prevention of bleeding episodes in patients with von Willebrand disease, marking a significant development in the treatment landscape as there are currently no products on the market targeting the same mechanism [1] Group 2 - SR604 injection is a humanized high-affinity monoclonal antibody that specifically inhibits the anticoagulant function of human activated protein C [1] - As of the date of the announcement, there are no other products with the same target approved globally, and no antibody drugs have been approved for the prevention treatment of von Willebrand disease [1]